Foundations Investment Advisors LLC Grows Position in Becton, Dickinson and Company (NYSE:BDX)

Foundations Investment Advisors LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,305 shares of the medical instruments supplier’s stock after purchasing an additional 141 shares during the period. Foundations Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $316,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Ontario Teachers Pension Plan Board grew its holdings in shares of Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock worth $461,158,000 after acquiring an additional 1,263,391 shares during the period. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after buying an additional 516,427 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after buying an additional 512,566 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after buying an additional 473,914 shares in the last quarter. Finally, Morgan Stanley grew its stake in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after acquiring an additional 435,168 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Barclays upped their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $281.40.

View Our Latest Stock Analysis on BDX

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. Insiders have sold 8,597 shares of company stock valued at $2,028,786 over the last three months. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $236.30 on Friday. The stock has a market capitalization of $68.29 billion, a P/E ratio of 52.05, a P/E/G ratio of 2.07 and a beta of 0.45. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The firm’s 50-day moving average is $238.15 and its two-hundred day moving average is $239.03.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the company earned $2.86 earnings per share. Equities analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.